Abstract
Endocrine pancreatic tumors (EPTs) are neoplasms with an annual clinically recognized incidence of approximately five cases per 1 million people. The majority of clinically discovered EPTs are functionally active, leading to a recognizable clinical syndrome resulting from a hormone-excess state. These tumors are called “functioning EPTs.” Tumorigenesis is believed to be a multistep process, involving an accumulation of genetic changes that results in the acquisition of the properties of tumorous growth. A comprehensive identification of genetic changes in a tumor could facilitate the discovery of genetic events responsible for the tumor initiation and progression. In past years, powerful technologies such as comparative genomic hybridization (CGH) and microarray methods have been developed for a genomewide survey of genetic alterations. The technology CGH is a useful tool to examine an entire genome for changes in DNA sequence copy number. Unlike classical cytogenetic methods, CGH analysis does not require cell culture to obtain metaphases from patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
